Antibacterial

<p>TP0586352 is a potent inhibitor of LpxC, exhibiting efficacy against carbapenem-resistant strains of Klebsiella pneumoniae without inducing cardiovascular risks</p>

Oligomycin B is an antibiotic isolated from marine Streptomyces, is an eukaryotic ATP synthase inhibitor, induces apoptosis.

<p>Azidocillin, a semi-synthetic oral β-lactam antibiotic, treats various bacterial infections including osteitis and septicemia.</p>

<p>Antibacterial agent 150 (compound 5g) exhibits potent activity against a wide range of bacteria, including both Gram-positive and Gram-negative species, with</p>

<p>Amoxycillin arginine salt is a bioactive chemical.</p>

<p>Isocryptomerin, from Selaginella tamariscina, is an antifungal that depolarizes membranes and has anticancer, antibacterial effects.</p>

<p>Compound 1b, also known as Antibacterial agent 145, targets the bacterial iron uptake pathway to exert its effects.</p>

<p>Compound A11 is a potent antibacterial, with MIC 0.00191 μg/mL against MRSA, outperforming tiamulin and retapamulin by 162x and 32x.</p>

<p>Framycetin is an aminoglycoside antibiotic and it also inhibits hammerhead ribozyme (Ki: 13.5 μM).</p>

<p>Omadacycline: an aminomethylcycline antibiotic, cidal against four Streptococcus pneumoniae strains.</p>

<p>Tigecycline hydrochloride is a first-in-class, broad-spectrum antibiotic. It also has activity against antibiotic-resistant organisms.</p>

<p>Maximin 15, an antimicrobial peptide originating from toad brain, exhibits activity against Staphylococcus aureus, Escherichia coli, and Bacillus subtilis, with</p>

<p>Globomycin: a lipopeptide antibiotic that irreversibly inhibits signal peptidase II, blocking prolipoprotein processing.</p>

<p>Monensin, from Streptomyces cinnamonensis, inhibits Wnt/β-catenin. Potential anticancer agent.</p>

<p>SC 28538, a 5-nitroimidazole, matches metronidazole in potency against multiple pathogens in vitro.</p>

<p>Antibacterial agent 49 (example 12) is a antibacterial agent.</p>

<p>Cis-2-dodecenoic acid, identified in Burkholderia cenocepacia, disrupts bacterial quorum sensing, thereby inhibiting biofilm formation and the production of</p>

<p>Oritavancin, a semisynthetic antibiotic for skin infections, approved by FDA on August 6, 2014, targets resistant Gram-positive bacteria.</p>

C12-rrw-NH2 (Compound Lip7) is an antimicrobial agent effective against Gram-positive bacteria, particularly demonstrating significant activity against Methicillin-resistant Staphylococcus aureus (MRSA). It induces bacterial cell death by depolarizing the bacterial cell membrane, disrupting membrane integrity, causing nucleic acid and protein leakage, and promoting the generation of Reactive Oxygen Species (ROS). C12-rrw-NH2 is applicable in research focused on developing highly stable antimicrobial peptides.

<p>Altromycin E is a new pluramycin-like antibiotic.</p>